GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

lerodalcibep   Click here for help

GtoPdb Ligand ID: 14319

Synonyms: LIB-003 | LIB003 | sequence 3 [US10738102B2]
Approved drug
lerodalcibep is an approved drug
Compound class: Peptide
Comment: Lerodalcibep (LIB003) is a small protein that fuses an adnectin (designed to bind proprotein convertase subtilisin/kexin type 9 [PCSK9]) to human serum albumin to achieve an extended circulating half-life and ambient storage stability [3]. It behaves as a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor [1,4-6].
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
References
1. Katzmann JL, Laufs U. (2024)
PCSK9-directed therapies: an update.
Curr Opin Lipidol, 35 (3): 117-125. [PMID:38277255]
2. Klug EQ, Llerena S, Burgess LJ, Fourie N, Scott R, Vest J, Caldwell K, Kallend D, Stein EA, LIBERATE-HR Investigators. (2024)
Efficacy and Safety of Lerodalcibep in Patients With or at High Risk of Cardiovascular Disease: A Randomized Clinical Trial.
JAMA Cardiol, 9 (9): 800-807. [PMID:38958989]
3. Mitchell TS, Mealey R. (2020)
Compositions comprising PCSK9-binding molecules and methods of use.
Patent number: US10738102B2. Assignee: Lib Therapeutics LLC. Priority date: 20/09/2019. Publication date: 11/08/2020.
4. Raal F, Fourie N, Scott R, Blom D, De Vries Basson M, Kayikcioglu M, Caldwell K, Kallend D, Stein E, LIBerate-HeFH Investigators. (2023)
Long-term efficacy and safety of lerodalcibep in heterozygous familial hypercholesterolaemia: the LIBerate-HeFH trial.
Eur Heart J, 44 (40): 4272-4280. [PMID:37639462]
5. Sahebkar A, Karav S, Almahmeed W, Jamialahmadi T. (2025)
Lerodalcibep: Another Crucial Addition to the Dyslipidaemia Arsenal.
Rev Cardiovasc Med, 26 (9): 42070. [PMID:41089781]
6. Tomlinson B. (2025)
An up-to-date review of emerging biologic therapies for hypercholesterolemia.
Expert Opin Biol Ther, 25 (1): 69-78. [PMID:39668448]